Vecima Announces Creation of Office of the CTO and Executive Leadership Changes
Vecima Networks Inc. (TSX: VCM) announced today that it has made several organizational changes across the executive leadership team in alignment with the company’s growth and operational objectives.
Mr. Clay McCreery has been appointed Chief Operating Officer. Mr. McCreery previously served as Chief Revenue Officer for Vecima, as well as managing operations for the Content Delivery & Storage business unit. He joined Vecima through the acquisition of Concurrent Technology in 2017. Prior to joining Concurrent, Mr. McCreery was Senior Vice President of Sales of North America at ARRIS for 14 years. During his tenure there, he helped integrate several key acquisitions enabling ARRIS’ market share growth in Access Technologies, DOCSIS Services, and Content Delivery. “This is a pivotal time for the company and the industries we serve. I am thrilled to be part of an organization with the vision and determination to help our customers transition their networks for next-generation services,” said Mr. McCreery.
Mr. Colin Howlett has been appointed Chief Technology Officer and will lead the newly created Office of the CTO. Mr. Howlett previously served as Vice President of Architecture at Vecima, and his tenure with the company spans 23 years, leading engineering and architecture teams. His technical expertise spans a wide breadth, including wireless, wireline, RF, and software engineering. “Throughout my previous roles at Vecima, the aspect I’ve enjoyed most is partnering with the customers we serve to develop unique and compelling solutions to their technical challenges,” said Mr. Howlett. “I look forward to leading a team of world-class technology experts and industry thought leaders as we expand our reach.”
Mr. Kyle Goodwin has been promoted to SVP & General Manager of the Content Delivery & Storage business unit. Mr. Goodwin previously led Concurrent Technology’s research and development portfolio of products through a time of transition in the service provider industry. Prior to joining Concurrent, he spent time in the telecommunications, financial technology, and insurance industries with Motorola, PrimeRevenue, S1 Corporation, and Aflac. Mr. Goodwin is also a Steering Board Member of the DVB Project, an industry-led consortium defining the global standard for digital television.
Mr. Ryan Nicometo has been promoted to SVP & General Manager of the Video & Broadband Solutions business unit. Mr. Nicometo, who also joined Vecima from the acquisition of Concurrent Technology, brings 21 years of experience in the service provider space to his role. Prior to joining Concurrent, he held leadership roles at ARRIS Group, CCI Systems, and Motorola. While at Motorola and ARRIS, he helped integrate technology and talent from several acquisitions across roles in sales and product management.
Mr. Goodwin and Mr. Nicometo will report to Mr. McCreery in their new roles with the company.
“Both Ryan and Kyle have been key members of the management team and have been significant contributors in the success of the company over the last several years,” said Mr. McCreery.
“I am very excited to have Clay, Colin, Kyle, and Ryan take on expanded roles within the Vecima leadership team as we continue to execute on our strategy to serve our global service provider and broadcast customers with a powerful suite of products and technologies that fuel a more connected world,” said Mr. Sumit Kumar, President and Chief Executive Officer of Vecima. “Vecima is positioned for growth and investing in the futures of the industries we serve.”
About Vecima
Vecima Networks Inc. is a global leader focused on developing integrated hardware and scalable software solutions for broadband access, content delivery and telematics. We enable the world’s leading innovators to advance, connect, entertain, and analyze. We build technologies that transform content delivery and storage, enable high-capacity broadband network access, and streamline data analytics. For more information, please visit our website at www.vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005209/en/
Contact information
Vecima Networks
Investor Relations – 250-881-1982
invest@vecima.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom